{"entity":{"id":"paper-epipangi-dx-clin-cancer-res-2021","kind":"paper","name":"EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers","aka":[],"tldr":"An academic blood test reading DNA methylation that aims to find six digestive-system cancers at once and say which organ the signal comes from.","summary":"Kandimalla and colleagues used methylation data from 1,781 tumour and adjacent normal tissues to design a targeted bisulphite sequencing panel of 67,832 regions, then validated it in 300 cell-free DNA specimens. Cancer-specific panels reached areas under the curve of 0.98 (colorectal), 0.98 (hepatocellular), 0.94 (oesophageal squamous), 0.90 (gastric), 0.90 (oesophageal adenocarcinoma) and 0.85 (pancreatic ductal); a pan-gastrointestinal panel detected all of them with an area under the curve of 0.88; and a tissue-of-origin panel, EpiPanGI Dx, predicted the organ with accuracy of 0.85 to 0.95 for most.","asOf":"2026-10-29","links":[{"label":"Clinical Cancer Research 2021","url":"https://doi.org/10.1158/1078-0432.CCR-21-1982"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34465601/"}],"tags":[],"related":[],"cancers":["colorectal","hcc","gastric","esophageal","pancreatic"],"sections":["early-detection"],"technologies":["mced","cfdna-methylation-testing"],"targets":[],"drugs":["epipangi-dx"],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.CCR-21-1982","pmid":"34465601","authors":"Kandimalla R, Xu J, Link A, et al.","paperType":"translational","findings":["Pan-gastrointestinal panel area under the curve 0.88.","Tissue-of-origin accuracy 0.85 to 0.95 for most gastrointestinal cancers."],"whatItMeans":"A research assay, not a product; it shows that one methylation panel can cover the digestive cancers.","caveats":["300 plasma specimens; no sensitivity at a stated specificity in the abstract.","No prospective or screening data."],"changedPractice":false,"participants":300},"route":"/key-papers/paper-epipangi-dx-clin-cancer-res-2021/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"epipangi-dx","kind":"drug","name":"EpiPanGI Dx","route":"/drugs/epipangi-dx/"}],"institution":[{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/"}],"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}]}}